TOKYO, Mar 17 (Pulse News Wire) – Cellsource CO.,LTD. (4880.T) reported a revenue increase of ¥800 million for the quarter ending October 2026 compared to the same period last year.
The growth was primarily attributed to higher sales from orthopedic support services, which contributed ¥44 million more than the previous quarter due to increased demand. Additionally, the company noted a reduction in revenue from its hybrid model service, resulting in a decrease of ¥509 million.
However, self-pay specialized treatments saw an increase of ¥300 million, while the high-end hybrid model experienced a rise of ¥27 million. Overall, the company's operating profit improved by ¥40 million, driven by strong performance in key areas despite a slight decline in certain segments.
🟢 Confidence: High AI-translated content.